199 related articles for article (PubMed ID: 23263910)
1. Three or four fractions per week in postoperative high-dose-rate brachytherapy for endometrial carcinoma. The long-term results on vaginal relapses and toxicity.
Valduvieco I; Rovirosa Á; Herreros A; Romera I; Ríos I; Ascaso C; Sánchez-Reyes A; Arenas M; Pahisa J; Biete A
Clin Transl Oncol; 2013 Aug; 15(8):602-7. PubMed ID: 23263910
[TBL] [Abstract][Full Text] [Related]
2. Vaginal-cuff control and toxicity results of a daily HDR brachytherapy schedule in endometrial cancer patients.
Ríos I; Rovirosa A; Ascaso C; Valduvieco I; Herreros A; Castilla L; Sabater S; Holub K; Pahisa J; Biete A; Arenas M
Clin Transl Oncol; 2016 Sep; 18(9):925-30. PubMed ID: 26661111
[TBL] [Abstract][Full Text] [Related]
3. Can we shorten the overall treatment time in postoperative brachytherapy of endometrial carcinoma? Comparison of two brachytherapy schedules.
Rovirosa A; Ascaso C; Arenas M; Sabater S; Herreros A; Camarasa A; Rios I; Holub K; Pahisa J; Biete A
Radiother Oncol; 2015 Jul; 116(1):143-8. PubMed ID: 26194144
[TBL] [Abstract][Full Text] [Related]
4. Is one brachytherapy fraction of 7 Gy similar to more fractions after external beam irradiation in postoperative endometrial carcinoma?
Zhang Y; Ascaso C; Herreros A; Sánchez J; Del Pino M; Torné A; Li Y; Sabater S; Arenas M; Biete A; Rovirosa Á
Clin Transl Oncol; 2020 Aug; 22(8):1295-1302. PubMed ID: 31865604
[TBL] [Abstract][Full Text] [Related]
5. Three or four fractions of 4-5 Gy per week in postoperative high-dose-rate brachytherapy for endometrial carcinoma.
Rovirosa A; Ascaso C; Sánchez-Reyes A; Herreros A; Abellana R; Pahisa J; Lejarcegui JA; Biete A
Int J Radiat Oncol Biol Phys; 2011 Oct; 81(2):418-23. PubMed ID: 20800388
[TBL] [Abstract][Full Text] [Related]
6. A new short daily brachytherapy schedule in postoperative endometrial carcinoma. Preliminary results.
Rovirosa Á; Ascaso C; Herreros A; Sánchez J; Holub K; Camarasa A; Sabater S; Oses G; García-Miguel J; Rivera Y; Arenas M
Brachytherapy; 2017; 16(1):147-152. PubMed ID: 28029590
[TBL] [Abstract][Full Text] [Related]
7. Daily schedule for high-dose-rate brachytherapy in postoperative treatment of endometrial carcinoma.
Rovirosa A; Valduvieco I; Ascaso C; Herreros A; Bautista C; Romera I; Arenas M; Pahisa J; Biete A
Clin Transl Oncol; 2013 Feb; 15(2):111-6. PubMed ID: 22855177
[TBL] [Abstract][Full Text] [Related]
8. Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial.
Nout RA; Smit VT; Putter H; Jürgenliemk-Schulz IM; Jobsen JJ; Lutgens LC; van der Steen-Banasik EM; Mens JW; Slot A; Kroese MC; van Bunningen BN; Ansink AC; van Putten WL; Creutzberg CL;
Lancet; 2010 Mar; 375(9717):816-23. PubMed ID: 20206777
[TBL] [Abstract][Full Text] [Related]
9. Comparative results of three short brachytherapy schedules as exclusive treatment in postoperative endometrial carcinoma.
Rovirosa Á; Herreros A; Camacho C; Ascaso C; Sánchez J; Cortés S; Sabater S; Solà J; Torné A; Arenas M
Brachytherapy; 2017; 16(6):1169-1174. PubMed ID: 28801116
[TBL] [Abstract][Full Text] [Related]
10. Does an Algorithmic Approach to Using Brachytherapy and External Beam Radiation Result in Good Function, Local Control Rates, and Low Morbidity in Patients With Extremity Soft Tissue Sarcoma?
Klein J; Ghasem A; Huntley S; Donaldson N; Keisch M; Conway S
Clin Orthop Relat Res; 2018 Mar; 476(3):634-644. PubMed ID: 29443850
[TBL] [Abstract][Full Text] [Related]
11. Do vaginal recurrence rates differ among adjuvant vaginal brachytherapy regimens in early-stage endometrial cancer?
Ager BJ; Francis SR; Do OA; Huang YJ; Soisson AP; Dodson MK; Werner TL; Sause WT; Grant JD; Gaffney DK
Brachytherapy; 2019; 18(4):453-461. PubMed ID: 31005603
[TBL] [Abstract][Full Text] [Related]
12. High dose rate intracavitary brachytherapy for recurrent or residual lesions in the vaginal cuff: results in post-hysterectomy patients with carcinoma of the cervix.
Ogino I; Kitamura T; Okamoto N; Nakayama H; Matsubara S
Int J Gynecol Cancer; 2001; 11(1):61-8. PubMed ID: 11285035
[TBL] [Abstract][Full Text] [Related]
13. Preliminary results of a vaginal constraint for reducing G2 late vaginal complications after postoperative brachytherapy in endometrial cancer: a prospective analysis.
Zhang Y; Gomez G; Ascaso C; Herreros A; Fornes B; Mases J; Rochera J; Tagliaferri L; Sabater S; Torne A; Biete A; Rovirosa Á
Clin Transl Oncol; 2022 May; 24(5):875-881. PubMed ID: 34854030
[TBL] [Abstract][Full Text] [Related]
14. Definitive salvage for vaginal recurrence of endometrial cancer: the impact of modern intensity-modulated-radiotherapy with image-based HDR brachytherapy and the interplay of the PORTEC 1 risk stratification.
Vargo JA; Kim H; Houser CJ; Berhane H; Sukumvanich P; Olawaiye AB; Kelley JL; Edwards RP; Comerci JT; Huang M; Courtney-Brooks M; Beriwal S
Radiother Oncol; 2014 Oct; 113(1):126-31. PubMed ID: 25241996
[TBL] [Abstract][Full Text] [Related]
15. High-dose-rate brachytherapy alone post-hysterectomy for endometrial cancer.
MacLeod C; Fowler A; Duval P; D'Costa I; Dalrymple C; Firth I; Elliott P; Atkinson K; Carter J
Int J Radiat Oncol Biol Phys; 1998 Dec; 42(5):1033-9. PubMed ID: 9869226
[TBL] [Abstract][Full Text] [Related]
16. Recurrences and toxicity after adjuvant vaginal brachytherapy in Stage I-II endometrial cancer: A monoinstitutional experience.
Perrucci E; Lancellotta V; Bini V; Zucchetti C; Mariucci C; Montesi G; Saccia S; Palumbo I; Aristei C
Brachytherapy; 2016; 15(2):177-84. PubMed ID: 26727332
[TBL] [Abstract][Full Text] [Related]
17. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838
[TBL] [Abstract][Full Text] [Related]
18. Prostate Specific Antigen (PSA) as Predicting Marker for Clinical Outcome and Evaluation of Early Toxicity Rate after High-Dose Rate Brachytherapy (HDR-BT) in Combination with Additional External Beam Radiation Therapy (EBRT) for High Risk Prostate Cancer.
Ecke TH; Huang-Tiel HJ; Golka K; Selinski S; Geis BC; Koswig S; Bathe K; Hallmann S; Gerullis H
Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27834929
[TBL] [Abstract][Full Text] [Related]
19. Are 7.5 Gy×2 fractions more efficient than 6 Gy×3 in exclusive postoperative endometrial cancer brachytherapy? A clinical and dosimetrical analysis.
Noorian F; Abellana R; Zhang Y; Herreros A; Baltrons C; Lancellota V; Tagliaferri L; Sabater S; Torne A; Rovirosa A
Radiother Oncol; 2023 Dec; 189():109909. PubMed ID: 37699447
[TBL] [Abstract][Full Text] [Related]
20. [The vaginal stump recurrence rate in endometrial carcinoma in relation to the target volume of postoperative HDR-afterloading brachytherapy].
Kloetzer KH; Günther R; Wendt T
Strahlenther Onkol; 1997 Jan; 173(1):13-7. PubMed ID: 9082580
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
